Abiomed says it struck a deal to extend the statute of limitations on any charges that might arise from a U.S. Justice Dept. probe of the marketing for its Impella heart pump and raised its estimate of the legal fees from the investigation.
Abiomed (NSDQ:ABMD) said it struck a deal with federal prosecutors to extend the tolling agreement on a probe of its marketing of its flagship Impella heart pump.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1l0dxpe
Cap comentari:
Publica un comentari a l'entrada